Processa Pharmaceuticals (NASDAQ: PCSA) regains Nasdaq bid rule compliance

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. reported that on January 6, 2026 it received written notice from the Nasdaq Stock Market staff that the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(a)(2). Nasdaq indicated that the bid-price deficiency matter is now closed, meaning the company’s common stock remains eligible to trade on the Nasdaq Capital Market under its existing listing standard.

Positive

• Regained compliance with Nasdaq’s $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market, and Nasdaq has closed the bid-price deficiency matter.

Negative

• None.

Insights

Equity listing & capital markets analyst

Nasdaq confirms Processa is back in compliance with its $1.00 bid rule.

Processa Pharmaceuticals disclosed that Nasdaq’s Listing Qualifications Staff notified the company on January 6, 2026 it has regained compliance with the $1.00 minimum closing bid price requirement under Rule 5550(a)(2) for the Nasdaq Capital Market. Nasdaq also stated that the matter is now closed.

This type of notice removes an active bid-price deficiency issue, which can otherwise lead to delisting if not cured within specified timeframes. Keeping the common stock on the Nasdaq Capital Market helps preserve trading continuity and access to that exchange’s investor base, based on the information provided.

Future company communications and periodic reports will show whether the share price continues to meet Nasdaq’s ongoing standards, but this notice confirms that, as of the stated date, the company satisfied the minimum bid requirement for continued listing.

false 0001533743 0001533743 2026-01-06 2026-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): 01/06/2026

Commission file number 001-39531

PROCESSA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		45-1539785
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

601 21^st Street, Suite 300 Vero Beach, FL 32960

(Address of Principal Executive Offices, Including Zip Code)

(772) 453-2899

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock: Par value $.0001		PCSA		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 6, 2026, Processa Pharmaceuticals, Inc. (the “Company”) received written notification from the NASDAQ Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nastadq Capital Market pursuant to NASDAQ Listing Rule 5550(a)(2) (the “Minimum Bid Price”) and that the matter is now closed.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit		Description
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on January 7, 2026.

	PROCESSA PHARMACEUTICALS, INC.
	Registrant
	By:	/s/ George Ng
		George Ng
		Chief Executive Officer

FAQ

What did Processa Pharmaceuticals (PCSA) announce in this 8-K?

Processa Pharmaceuticals reported that on January 6, 2026 it received written notification from Nasdaq that it has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market and that the matter is now closed.

Which Nasdaq rule did Processa Pharmaceuticals (PCSA) regain compliance with?

The company regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a $1.00 minimum closing bid price for continued listing on the Nasdaq Capital Market.

What does Nasdaq’s notice mean for Processa Pharmaceuticals’ Nasdaq Capital Market listing?

Nasdaq’s notice confirms that Processa Pharmaceuticals’ common stock currently meets the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market, and Nasdaq has closed the prior bid-price deficiency matter.

When did Nasdaq inform Processa Pharmaceuticals that it was back in compliance?

Nasdaq’s Listing Qualifications Staff sent written notification to Processa Pharmaceuticals on January 6, 2026 confirming that the company had regained compliance with the minimum bid price requirement.

Does this 8-K include any new financial statements or transaction details for PCSA?

No. The 8-K, under Item 8.01 Other Events, focuses on Nasdaq’s notification that Processa Pharmaceuticals has regained compliance with the $1.00 minimum closing bid price requirement; it does not present new financial statements or major transaction terms.